• Perospirone Inhibits Coronary Kv1.5 Channels

  2026-09-28

  A 2025 Journal of Applied Toxicology study identifies a previously unrecognized vascular ion-channel action of Perospirone in freshly isolated rabbit coronary arterial smooth muscle cells. The findings connect an established serotonergic and dopaminergic antipsychotic mechanism with concentration-dependent, use-independent inhibition of vascular Kv currents, while emphasizing that the evidence remains preclinical and mechanistic.

• Clozapine and Prefrontal Circuit Assay Design

  2026-09-28

  Clozapine is an atypical antipsychotic medication whose receptor and ERK1/2 effects can help researchers probe prefrontal biology. This article explains how to use it alongside emerging magnetic-stimulation findings without confusing distinct mechanisms or overextending translational claims.

• Antiemetics and Renal OCT2/MATE1 Drug Secretion

  2026-09-27

  George and colleagues compared five 5-HT3 antagonist antiemetics in cell-based assays and found that their inhibition of renal OCT2 and MATE1 varied substantially by compound and transporter. The results identify a potential mechanism for altered renal secretion of organic cation drugs, while remaining in vitro evidence that does not by itself establish clinical drug interactions.

• Escitalopram in Cell Assay Workflows

  2026-09-26

  This scenario-driven guide explains how Escitalopram (SKU B1183) can be used thoughtfully in serotonergic cell research, from stock preparation to assay interpretation. It separates transporter evidence from cytotoxicity outcomes and connects laboratory findings to clinical evidence without overstating what either can establish.

• Fluoxetine HCl Beyond Serotonin-First Models

  2026-09-25

  Fluoxetine HCl is a useful serotonergic probe—but its value in translational neuroscience depends on asking what the experiment can and cannot establish. Developmental SSRI findings point to persistent, motivation-selective changes involving nucleus accumbens mu-opioid receptors, making a case for separating drug target engagement from circuit-level outcomes.

• Amitriptyline HCl: Practical Research Workflow

  2026-09-25

  Amitriptyline HCl (SKU B2231) provides a documented small-molecule perturbation for receptor and signaling studies, with product-specified potency, solubility, and storage information to guide setup. Use it in controlled neuropharmacology experiments, not as a selective probe or standalone evidence of disease-model efficacy without orthogonal validation.

• 6-OHDA Hydrochloride: A Model-Design Guide

  2026-09-24

  Explore how 6-OHDA hydrochloride creates catecholaminergic injury models and how to interpret its effects without confusing cellular uptake with functional outcomes. This guide also draws a careful assay-design lesson from research on nanoparticle protein coronas.

• SAR131675 VEGFR-3 Inhibitor: Applied Workflows

  2026-09-24

  Use SAR131675 to probe VEGFR-3-dependent endothelial signaling with nanomolar biochemical and cell-based readouts, while separating receptor-specific effects from broader angiogenic phenotypes. This workflow emphasizes dose selection, formulation checks, and careful interpretation of a separate nicotine–kidney disease review used as a model for endpoint design—not evidence of a kidney indication.

• Adefovir Workflows for HBV and OAT1 Research

  2026-09-23

  Build reproducible Adefovir experiments around two distinct strengths: HBV polymerase inhibition and OAT1 substrate behavior. A case report of phosphate-wasting bone disease adds a practical reminder to pair antiviral work with renal and mineral-metabolism questions when those are within scope.

• CBD, Orofacial Pain, and Affective Circuitry

  2026-09-23

  A 2026 Brain Research Bulletin study shows that cannabidiol (CBD) reduces both inflammatory orofacial nociception and pain-associated affective deficits in mice through coordinated peripheral endocannabinoid, central pain-network, and serotonergic mechanisms. Its integrated behavioral, biochemical, and fiber-photometry design provides a useful framework for studying pain as a sensory, emotional, and cognitive disorder rather than as an isolated reflex.

• Neuromedin S (rat): Practical GPCR Assay Guide

  2026-09-22

  Neuromedin S (rat), SKU B5466, provides a defined peptide agonist for controlled studies of neuromedin U receptor signaling and GPCR/G protein signaling. This guide covers preparation, assay controls, and stability handling; the reagent is for scientific research workflows only and should not be used for diagnostic, therapeutic, or medical purposes.

• Amikacin Sulfate: Targeting NTM Granulomas

  2026-09-22

  Amikacin Sulfate is more than a bactericidal aminoglycoside: it is a platform for asking how antibiotic exposure can be concentrated where Mycobacterium avium persists. This article connects ribosomal mechanism, dendritic-cell delivery, experimental controls, and translational decision-making for researchers developing more precise NTM therapies.

• Escitalopram Workflows for Serotonergic Research

  2026-09-21

  Build reproducible Escitalopram assays around transporter selectivity, vehicle control, and phenotype-aware analysis. This workflow connects 5-HT reuptake inhibition with practical antidepressant research and the anxious-depression findings reported in a controlled augmentation study.

• VEGFC–Macrophage Signaling in NASH Fibrosis

  2026-09-21

  This study identifies a hepatocyte-derived VEGFC–VEGFR-3–CCL2/CCR2 axis that promotes inflammatory macrophage recruitment and limits macrophage phenotypic resolution during high-fat diet-induced hepatic fibrosis. Pharmacological VEGFR-3 inhibition, hepatocyte-specific Vegfc deletion, human clinical data, and cell-based experiments together position VEGFC suppression as a mechanistic component of naringin-mediated protection.

• Targeted Amikacin Delivery into Mycobacterial Granulomas

  2026-09-20

  Montes-Worboys and colleagues developed a dendritic-cell carrier system to direct fluorescently traceable amikacin into Mycobacterium avium granulomas in infected mice. The study provides proof of localization and supports cell-mediated delivery as a strategy for increasing antibiotic exposure at infected tissue, while stopping short of demonstrating superior therapeutic efficacy.

7942 records 1/530 page Next 12345 下5页 Last page